Study: NCT01244035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.